Company / Working Capital
Gossamer Bio, Inc. Working Capital History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$104.2M
FY2025
5-year range
$104.2M / $291.9M
FY2021-FY2025
Trend
-60.7%
vs FY2024
Sector context
#192 of 213
Health Care
What the data says
Among 213 Health Care companies, Gossamer Bio, Inc. is in the bottom 10% for working capital. Working Capital has fluctuated over the past 8 years, ranging from $104M in FY2025 to $484M in FY2020.
Based on SEC 10-K filings.
$104M in FY2025 with a 5-year CAGR of -26.4%.
Declined from $255M to $104M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -21.2%
- 5-Year CAGR
- -26.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 213This company $104.2M Sector average $934.6M
▼
-88.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -26.4%, indicating a declining trend.
- In FY2025, working capital decreased 60.7% year-over-year.
- Ranks #192 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -9.62 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $104.2M | -60.7% |
| FY2024 | $264.9M | +3.9% |
| FY2023 | $254.9M | +19.9% |
| FY2022 | $212.7M | -27.2% |
| FY2021 | $291.9M | -39.6% |
| FY2020 | $483.7M | +29.9% |
| FY2019 | $372.4M | +76.0% |
| FY2018 | $211.6M | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026